Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Completion of Patient Enrollment, PI Study of MultiStem, Athersys (ATHX)

ATHX has completed patient enrollment of the single dose arm of a clinical study involving administration of MultiStem(NYSE:R) to patients being treated for leukemia or other blood born cancers.

The study involves administration of a single or multiple doses of MultiStem, an allogeneic cell therapy product, to patients following radiation therapy and a donor derived hematopoietic stem cell transplant.

  • The Phase I clinical trial is an open label, multi-center dose escalation trial evaluating the safety and maximum tolerated dose of a single or multiple dose administration of allogeneic MultiStem delivered intravenously following standard allogeneic hematopoietic stem cell transplant;
  • Patients enrolled in the study receive either a low, medium or high dose of MultiStem, and are being evaluated against current standard of care;
  • Treatment of the final patient for the single dose arm occurred 12/30/10, consistent with the previously stated goal of completing enrollment prior to year-end, while enrollment in the multiple dose arm will continue and is intended to be completed in 2011;
  • The study is being conducted at multiple bone marrow transplant centers in the US, including Oregon Health & Science University Medical Center, Texas Transplant Institute, University Hospitals Case Medical Center, University of Pennsylvania, Mayo Clinic Arizona and several other sites;
  • Patients receiving such transplants are typically at risk for Graft-Versus-Host Disease (GVHD), as well as other complications, such as tissue damage from the radiation and chemotherapy treatments that are conducted prior to the transplant;
  • Initial results of safety information from the single dose arm of this trial are expected to be announced following the completion of patient evaluation periods and subsequent analysis of data.